{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-069674","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.279900+00:00","generated_at":"2026-06-01T05:59:05.797020+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Relay Therapeutics announces Pfizer collaboration and three new pipeline programs","bullets":["Clinical collaboration with Pfizer to evaluate RLY-2608 + atirmociclib + fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024.","New pre-clinical programs: vascular malformations, Fabry disease non-inhibitory chaperone, and NRAS-selective inhibitor, targeting over 200,000 U.S. patients.","RLY-2608 clinical development in vascular malformations expected Q1 2025; Fabry disease chaperone and NRAS inhibitor to enter clinic in H2 2025.","Cash runway guidance unchanged; $750 million expected to fund operations into second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-069674","json":"https://secwatch.observer/filing/0000950170-24-069674.json","markdown":"https://secwatch.observer/filing/0000950170-24-069674.md","text":"https://secwatch.observer/filing/0000950170-24-069674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024069674/0000950170-24-069674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024069674/rlay-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:59:05.797020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}